Publications
104
Citations
1,765
Est. group size
~3
Recurring co-author estimate
Active years
27
Publishing since 1999
Ming Poi's research focuses on cancer biology and treatment, spanning topics such as lung cancer, multiple myeloma, and leukemia. Work includes studying molecular markers (like B7-H3 and HER3) that could guide targeted therapies, testing combinations of cancer drugs in laboratory models, and examining genetic and clinical factors that affect patient outcomes, including participation in cancer genomic studies in underserved rural populations.
Publication output has fluctuated over the past decade, with a notable spike in 2023 followed by a return to a more moderate, steady pace in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes
Clinical Cancer Research · 2025
- Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells
Anticancer Research · 2025
- Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma
Research Square · 2025
- P1.11.59 Effect of IFNG Expression Levels on Real-World Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Receiving Immunotherapy
Journal of Thoracic Oncology · 2025
- Data from Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes
2025
- Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes.
Journal of Clinical Oncology · 2024
- Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations
Cancer Research · 2024
- Genetic Alteration of<i>p18<sup>INK4C</sup></i>and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant
Anticancer Research · 2024
- P1.12-05 Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC
Journal of Thoracic Oncology · 2023
- Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky
The Journal of Rural Health · 2020
- Abstract IA27: An innovative approach to improve clinical trials using adaptive in silico design
Cancer Epidemiology Biomarkers & Prevention · 2020
- Abstract A001: Improving cancer germline testing in rural Appalachian populations with ORIEN
Cancer Epidemiology Biomarkers & Prevention · 2020
- Quantification of miRNAs Co-Immunoprecipitated with Argonaute Proteins Using SYBR Green-Based qRT-PCR
Methods in molecular biology · 2017
- Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia
Drugs · 2016
- Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions
American Journal of Health-System Pharmacy · 2016
- Anticancer Research×6
- Molecular Carcinogenesis×3
- Journal of Clinical Oncology×3
- Cancer Research×3
- Leukemia & lymphoma/Leukemia and lymphoma×2
- Christopher M. Weghorst
Medicine · The Ohio State University
- Jian Zhu
Medicine · The Ohio State University
- Anna E. Vilgelm
Medicine · The Ohio State University
- Bhavneet Singh
Medicine · Indiana University
- Lindsey D. Mayo
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile